Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amniotic fluid or placental CD117 stem cells
- Development stage
- Unknown
- Lead developer
- Wake Forest University Health Sciences
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
Amniotic fluid or placental CD117 stem cells is an investigational cell therapy being developed by Wake Forest University Health Sciences for the treatment of progressive forms of multiple sclerosis (MS). The therapy consists of stem cells expressing the CD117 (c-Kit) marker, which are isolated from ethically sourced amniotic fluid or placental tissue. These cells are administered intrathecally into the spinal fluid to bypass the blood-brain barrier and deliver the cells directly to the central nervous system. The mechanism of action is thought to involve neuroprotection, immunomodulation, and potential remyelination, aimed at slowing or reversing the disability progression characteristic of primary and secondary progressive MS. It is currently being evaluated in a Phase I/II clinical trial.
- Other names
- Amniotic fluid stem cellsAFSCsCD117+ stem cellsc-Kit+ stem cellsPlacental CD117 stem cells
Beyond the preview
Go deeper on Amniotic fluid or placental CD117 stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amniotic fluid or placental CD117 stem cells.